Dividends & Buybacks · Jul 14, 2026

Genprex, Inc. announced a one-for-twenty-two (1:22) reverse stock split of its common stock, effective July 16, 2026…

GNPXGenprex, Inc.

Genprex, Inc. announced a one-for-twenty-two (1:22) reverse stock split of its common stock, effective July 16, 2026, to help regain compliance with Nasdaq's $1.00 minimum bid price requirement. The company also provided updates on its Acclaim-1 and Acclaim-3 clinical trials for its gene therapy programs. Genprex, Inc. is a biotechnology company focused on oncology and diabetes gene therapy.